GPP
ACER

Great Point Partners’s Acer Therapeutics Inc ACER Stock Holding History

Great Point Partners’s Portfolio ACER Stock Details ACER Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-58,461
Closed -$1.8M – 43
2018
Q3 		$1.8M Buy
+58,461
New +$1.57M 0.28% 27

Other funds holding ACER

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Great Point Partners's ACER Position: Q4 2018 in Review

Great Point Partners sold out of Acer Therapeutics Inc (ACER) in Q4 2018, closing a stake of 58,461 shares — an estimated $1.8M sold.

Great Point Partners first reported a position in ACER in Q3 2018 and held it in 1 quarter. The position peaked at $1.8M in Q3 2018. 28 funds tracked by Wall St. Rank hold ACER as of Q4 2018.

  • Great Point Partners reported no remaining Acer Therapeutics Inc position as of Q4 2018 after selling out during the quarter.
  • Great Point Partners sold 58,461 Acer Therapeutics Inc shares in Q4 2018, an estimated $1.8M.
  • Great Point Partners first reported a position in Acer Therapeutics Inc in Q3 2018 and held it in 1 quarter.
  • Great Point Partners's Acer Therapeutics Inc position peaked at $1.8M in Q3 2018.
  • 28 funds tracked by Wall St. Rank held Acer Therapeutics Inc as of Q4 2018.

Based on Great Point Partners's 13F filing for Q4 2018, filed 15 Feb 2019.